Opinion

Video

Fostering Next-Generation Expertise in Dry Eye

Author(s):

Laura Periman, MD,Kelly Nichols, OD

Experts discuss strategies for making dry eye care an appealing practice option for optometry students and supporting their success in this specialized field.

1:29 Evolution of Dry Eye Care

5:45 Diagnostic Shifts

8:50 Resources for Students

14:00 Proactive Dry Eye Care

19:50 Starting a Dry Eye Program

25:10 Treatment Approach

Related Videos
Quan Dong Nguyen, MD: Phase 2 Neptune Trial Advances Brepocitnib for Uveitis | Image Credit: Stanford University
Charles C. Wykoff, MD, PhD: Phase 1b/2a Results on Restoret for DME, nAMD | Image Credit: Retina Consultants of Texas
Christine N. Kay, MD | Image Credit: Atsena Therapeutics
Rahul N. Khurana, MD: Phase 1 Results on Vamikibart for Uveitic Macular Edema | Image Credit: Northern California Retina Vitreous Associates
Sunir J. Garg, MD: | Image Credit: Wills Eye Hospital
Christine N. Kay, MD: Interim Data on ATSN-201 Shows Promise for XLRS | Image Credit: Vitreo Retinal Associates
Related Content
FDA Approves Susvimo for Diabetic Macular Edema | Image Credit: FDA
February 4th 2025

FDA Approves Susvimo for Diabetic Macular Edema

Connor Iapoce
Ep 16: A Look at Qlosi for Presbyopia with Elad Kedar, MBA| Image Credit: HCPLive
January 28th 2025

New Insight: A Look at Qlosi for Presbyopia with Elad Kedar, MBA

Veeral Sheth, MD, MBA, FASRS, FACS Connor Iapoce
ONS-5010 for Wet AMD Secures Noninferiority in NORSE EIGHT Trial | Image Credit: Wills Eye Hospital
January 19th 2025

ONS-5010 for Wet AMD Secures Noninferiority in NORSE EIGHT Trial

Connor Iapoce
New Insight: A Look at Corneal Transplant Alternatives w/ John Sheets, PhD | Image Credit: HCPLive
September 5th 2024

New Insight: A Look at Corneal Transplant Alternatives w/ John Sheets, PhD

Connor Iapoce
SING IMT Device Secures Positive 6-Month Data for Late-Stage AMD | Image Credit: LinkedIn
January 14th 2025

SING IMT Device Secures Positive 6-Month Data for Late-Stage AMD

Connor Iapoce
OCU400 Improves 2-Year Vision in Retinitis Pigmentosa in Phase 1/2 Trial | Image Credit: Gundersen Health System
January 13th 2025

OCU400 Improves 2-Year Vision in Retinitis Pigmentosa in Phase 1/2 Trial

Connor Iapoce
© 2025 MJH Life Sciences

All rights reserved.